Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

Author： Wu Eric Q. Guerin Annie Yu Andrew P. Bollu Vamsi K. Guo Amy Griffin James D.

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.12, 2010-12, pp. : 2861-2869

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas Oliveria Susan A. Cziraky Mark Hirji Ishan Hamdan Muhammad Davis Catherine

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

By Signorovitch James E. Wu Eric Q. Betts Keith A. Parikh Kejal Kantor Evan Guo Amy Bollu Vamsi K. Williams Denise Wei L.J. DeAngelo Daniel J.

Current Medical Research and Opinion, Vol. 27, Iss. 6, 2011-06 ,pp. : 1263-1271

Informa Healthcare

Access to resources Recommend Favorite

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Dasatinib in the Treatment of Chronic Myeloid Leukemia

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria Copland Mhairi

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite